United States Biotechnology & Medical Research

TriSalus Life Sciences Inc (TLSI)

Track

Over the past 90 days, TriSalus Life Sciences Inc. saw significant insider activity, characterized by $1.82 million in total share purchases compared to $1,449 in sales. Four insiders, including the CEO and CFO, executed buy transactions on May 15, 2026, reflecting a notable shift toward accumulation following earlier divestments by various officers in March.
Ticker: TLSI Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for TriSalus Life Sciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 15 May 2026
Value US$3,996,779.81 | Price 175.48 | Shares 71,466 (+7.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-15 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
71,466 +7.6%
175.48
US$3,996,780 		71,466 +7.6% 175.48 US$3,996,780
2026-05-18 2026-05-15 B Purchase
Stansky Michael P
Non-Executive Director
39,933 -15.5%
15.41
US$1,683,273 		39,933 -15.5% 15.41 US$1,683,273
2026-05-18 2026-05-15 B Purchase
Stansky Michael P
Non-Executive Director
56,009 +6.1%
48.54
US$4,836,887 		56,009 +6.1% 48.54 US$4,836,887
2026-05-18 2026-05-15 B Purchase
2.9
Patience David

Chief Financial Officer

Officer
7,100 +2.6%
2.43
US$17,253 		7,100 +2.6% 2.43 US$17,253
2026-05-18 2026-05-15 B Purchase
2.9
Wahlstrom Mats
Non-Executive Director
60,000 +68.5%
2.53
US$151,800 		60,000 +68.5% 2.53 US$151,800
2026-05-18 2026-05-15 B Purchase
Gordon Gary B.
Non-Executive Director
10,000 +16.0%
2.46
US$24,600 		10,000 +16.0% 2.46 US$24,600
2026-05-18 2026-05-15 B Purchase
2.0
Szela Mary T

CEO and President

Executive Director
39,682 +3.9%
2.59
US$102,776 		39,682 +3.9% 2.59 US$102,776
2026-03-20 2026-03-17 S Sale
2.0
Szela Mary T

CEO and President

Executive Director
15,944 -2.1%
3.85
US$61,384 		15,944 -2.1% 3.85 US$61,384
2026-03-20 2026-03-16 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
419 -0.4%
4.12
US$1,726 		419 -0.4% 4.12 US$1,726
2026-03-20 2026-03-16 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
273 -0.3%
4.12
US$1,125 		273 -0.3% 4.12 US$1,125
2026-03-20 2026-03-16 S Sale
2.9
Cox Bryan F.

Chief of Research

Officer
579 -0.4%
4.12
US$2,385 		579 -0.4% 4.12 US$2,385
2026-03-20 2026-03-16 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
774 -0.6%
4.12
US$3,189 		774 -0.6% 4.12 US$3,189
2026-03-20 2026-03-12 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
1,589 -1.4%
4.09
US$6,499 		1,589 -1.4% 4.09 US$6,499
2026-03-20 2026-03-12 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
1,772 -1.8%
4.09
US$7,247 		1,772 -1.8% 4.09 US$7,247
2026-03-20 2026-03-12 S Sale
2.9
Cox Bryan F.

Chief of Research

Officer
1,467 -0.9%
4.09
US$6,000 		1,467 -0.9% 4.09 US$6,000
2026-03-20 2026-03-12 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
1,552 -1.2%
4.09
US$6,348 		1,552 -1.2% 4.09 US$6,348
2026-03-20 2026-03-11 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
1,449 -1.3%
4.13
US$5,984 		1,449 -1.3% 4.13 US$5,984
2026-03-20 2026-03-11 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
1,162 -1.2%
4.13
US$4,799 		1,162 -1.2% 4.13 US$4,799
2026-03-20 2026-03-11 S Sale
2.9
Cox Bryan F.

Chief of Research

Officer
1,138 -0.7%
4.13
US$4,700 		1,138 -0.7% 4.13 US$4,700
2026-03-20 2026-03-11 S Sale
2.0
Szela Mary T

CEO and President

Executive Director
4,358 -0.6%
4.13
US$17,999 		4,358 -0.6% 4.13 US$17,999
2026-03-20 2026-03-11 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
1,204 -0.9%
4.13
US$4,973 		1,204 -0.9% 4.13 US$4,973
2026-02-23 2026-02-23 B Purchase
Valle William
Non-Executive Director
30,487 +inf%
4.10
US$124,997 		30,487 +inf% 4.10 US$124,997
2026-02-23 2026-02-23 B Purchase
Stansky Michael P
Non-Executive Director
117,198 +142.1%
4.10
US$480,512 		117,198 +142.1% 4.10 US$480,512
2026-02-23 2026-02-23 B Purchase
Stansky Michael P
Non-Executive Director
243,900 +44.9%
4.10
US$999,990 		243,900 +44.9% 4.10 US$999,990
2026-02-23 2026-02-23 B Purchase
2.0
Szela Mary T

CEO and President

Executive Director
30,487 +4.1%
4.10
US$124,997 		30,487 +4.1% 4.10 US$124,997
2026-02-23 2026-02-23 B Purchase
2.9
Patience David

Chief Financial Officer

Officer
3,657 +1.4%
4.10
US$14,994 		3,657 +1.4% 4.10 US$14,994
2026-02-23 2026-02-23 B Purchase
Gordon Gary B.
Non-Executive Director
9,756 +inf%
4.10
US$40,000 		9,756 +inf% 4.10 US$40,000
2025-05-21 2025-05-19 S Sale
2.7
Marshak Richard

Chief Commercial Officer

Officer
6,597 -8.7%
5.18
US$34,172 		6,597 -8.7% 5.18 US$34,172
2025-05-21 2025-05-19 S Sale
2.6
Devlin Jodi

Chief of Clinical Operations

Officer
4,764 -8.3%
5.18
US$24,678 		4,764 -8.3% 5.18 US$24,678
2025-05-21 2025-05-19 S Sale
2.9
Cox Bryan F.

Chief of Research

Officer
4,764 -3.8%
5.18
US$24,678 		4,764 -3.8% 5.18 US$24,678
2025-05-21 2025-05-19 S Sale
2.6
Stevens Jennifer

Chief Regulatory Officer

Officer
8,704 -10.1%
5.18
US$45,087 		8,704 -10.1% 5.18 US$45,087
2025-02-06 2025-02-05 B Purchase
2.6
Young James Emmett

Chief Financial Officer

Officer
6,000 +25.0%
5.65
US$33,900 		6,000 +25.0% 5.65 US$33,900
2025-01-31 2025-01-30 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,010 +1.1%
5.28
US$26,453 		5,010 +1.1% 5.28 US$26,453
2025-01-31 2025-01-29 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,030 +1.2%
5.03
US$25,301 		5,030 +1.2% 5.03 US$25,301
2025-01-29 2025-01-28 B Purchase
3.2
Murphy Sean

Chief Manuf, Strategy&Bus Dev.

Executive Director
15,000 +8.2%
5.17
US$77,550 		15,000 +8.2% 5.17 US$77,550
2025-01-29 2025-01-28 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
4,716 +1.1%
5.12
US$24,146 		4,716 +1.1% 5.12 US$24,146
2025-01-29 2025-01-27 B Purchase
3.2
Murphy Sean

Chief Manuf, Strategy&Bus Dev.

Executive Director
15,000 +8.9%
5.31
US$79,650 		15,000 +8.9% 5.31 US$79,650
2025-01-29 2025-01-27 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
4,826 +1.1%
5.42
US$26,157 		4,826 +1.1% 5.42 US$26,157
2025-01-29 2025-01-27 B Purchase
2.6
Young James Emmett

Chief Financial Officer

Officer
24,000 +inf%
5.40
US$129,600 		24,000 +inf% 5.40 US$129,600
2024-12-19 2024-12-17 B Purchase
3.3
Frankenius Equity AB
Large shareholder
62,972 +1.0%
3.97
US$249,999 		62,972 +1.0% 3.97 US$249,999
2024-12-12 2024-12-10 S Sale
0.5
Desai Arjun JJ
Non-Executive Director
30,000 -10.8%
3.69
US$110,700 		30,000 -10.8% 3.69 US$110,700
2024-12-10 2024-12-10 PrS Proposed sale
0.5
Arjun Desai

Board of Directors

Non-Executive Director
30,000
4.50
US$135,000 		30,000 4.50 US$135,000
2024-11-25 2024-11-22 B Purchase
2.9
Wahlstrom Mats
Non-Executive Director Large shareholder
5,000 +46.6%
4.55
US$22,750 		5,000 +46.6% 4.55 US$22,750
2024-11-22 2024-11-21 B Purchase
2.9
Wahlstrom Mats
Non-Executive Director Large shareholder
8,687 +425.8%
4.44
US$38,570 		8,687 +425.8% 4.44 US$38,570
2024-11-22 2024-11-20 B Purchase
2.9
Wahlstrom Mats
Non-Executive Director Large shareholder
2,040 +inf%
4.16
US$8,486 		2,040 +inf% 4.16 US$8,486
2024-12-19 2024-10-05 S Sale
2.9
Cox Bryan F.

CHIEF SCIENTIFIC & MANUFACT.

Officer
314 -0.4%
4.44
US$1,394 		314 -0.4% 4.44 US$1,394
2024-09-13 2024-09-13 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
6,000 +1.6%
5.00
US$30,000 		6,000 +1.6% 5.00 US$30,000
2024-09-13 2024-09-13 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
1,295 +0.3%
4.83
US$6,255 		1,295 +0.3% 4.83 US$6,255
2024-09-13 2024-09-12 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
7,520 +2.0%
5.20
US$39,104 		7,520 +2.0% 5.20 US$39,104
2024-09-12 2024-09-10 B Purchase
2.0
Szela Mary T

CEO AND PRESIDENT

Executive Director
5,000 +1.4%
4.97
US$24,850 		5,000 +1.4% 4.97 US$24,850
2024-09-10 2024-08-28 S Sale
3.1
Martin George Kelly
Non-Executive Director
9 -0.0%
5.50
US$50 		9 -0.0% 5.50 US$50
Explore more

More insider trading research around TriSalus Life Sciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America